Metabolic dysfunction associated fatty liver disease and coronavirus disease 2019: clinical relationship and current management
Highlights • MAFLD was associated with increased risk and severity of COVID-19. • 31% of COVID-19 patients had MAFLD. • COVID-19 promoted liver injury and progression of MAFLD, especially in the youth. • The mechanism of liver injury in patients with COVID-19 was multifactorial. •Early screen and ac...
Main Authors: | Yanlan Xu, Xinyu Yang, Hua Bian, Mingfeng Xia |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-10-01
|
Series: | Lipids in Health and Disease |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12944-021-01564-z |
Similar Items
-
The Intersection of COVID-19 and Metabolic-Associated Fatty Liver Disease: An Overview of the Current Evidence
by: Mykhailo Buchynskyi, et al.
Published: (2023-04-01) -
Updated upper limits of normal serum alanine aminotrasferase levels for screening metabolic dysfunction-associated fatty liver disease in obese children
by: Yu-Cheng Lin, et al.
Published: (2022-12-01) -
Prevalence and risk factors of metabolic associated fatty liver disease in the contemporary South China population
by: Jiahua Fan, et al.
Published: (2021-09-01) -
Association of metabolic‐associated fatty liver disease and risk of severe coronavirus disease 2019 illness
by: Marianne Linley Sy‐Janairo, et al.
Published: (2021-01-01) -
Metabolic dysfunction-associated fatty liver disease: current therapeutic strategies
by: Khamis Al Hashmi, et al.
Published: (2024-03-01)